Montag A & Associates Inc. Sells 2,762 Shares of Stryker Corporation $SYK

Montag A & Associates Inc. decreased its holdings in shares of Stryker Corporation (NYSE:SYK) by 7.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 33,112 shares of the medical technology company’s stock after selling 2,762 shares during the quarter. Montag A & Associates Inc.’s holdings in Stryker were worth $10,909,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Godfrey Financial Associates Inc. purchased a new position in Stryker during the 4th quarter valued at $26,000. Sankala Group LLC purchased a new stake in Stryker in the fourth quarter worth $26,000. United Financial Planning Group LLC purchased a new stake in Stryker in the third quarter worth $27,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker during the fourth quarter worth $27,000. Finally, DJE Kapital AG bought a new stake in shares of Stryker during the fourth quarter worth $28,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Price Performance

Shares of SYK opened at $330.26 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a 50 day moving average price of $309.75 and a 200-day moving average price of $338.40. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The stock has a market capitalization of $126.61 billion, a PE ratio of 38.23, a PEG ratio of 2.08 and a beta of 0.77.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Barclays cut their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. The Goldman Sachs Group reiterated a “neutral” rating and set a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. Truist Financial restated a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Evercore set a $350.00 target price on shares of Stryker in a research report on Monday. Finally, Wells Fargo & Company decreased their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $395.10.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.